Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0006632003
Thu, 14.12.2023
MorphoSys AG
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA OR AUSTRALIA, SOUTH AFRICA, JAPAN OR IN ANY OTHER JURISDICTION IN WHICH, OR TO PERSONS IN ANY JURISDICTION TO WHOM, SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW
Media Release
Planegg/Munich, Germany, December 14, 2023
MorphoSys Places New Shares from Cash Capital Increase [ … ]
Thu, 14.12.2023
MorphoSys AG
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014
Planegg/Munich, Germany, December 14, 2023
Ad hoc: MorphoSys AG Places New Shares From Cash Capital Increase with Gross Proceeds Of Approximately EUR 102.7 million
MorphoSys AG (FSE: MOR; NASDAQ: MOR) (the “Company”) resolved to increase [ … ]
Wed, 13.12.2023
MorphoSys AG
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014
Planegg/Munich, Germany, December 13, 2023
Ad hoc: MorphoSys AG Launches Cash Capital Increase by way of Accelerated Bookbuilding Process
MorphoSys AG (FSE: MOR; NASDAQ: MOR) (the “Company”) announces that its Management Board, with the [ … ]
Mon, 11.12.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, December 10, 2023
MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
Pelabresib and ruxolitinib combination significantly reduced spleen size, with an SVR35 response rate nearly double that of placebo plus ruxolitinib
Showed a strong positive trend in reducing [ … ]
Mon, 20.11.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, November 20, 2023
MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
MANIFEST-2 met primary endpoint, nearly doubling SVR35 response rate (66% versus 35%)
The key secondary [ … ]
Mon, 20.11.2023
MorphoSys AG
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014
Planegg/Munich, Germany, November 20, 2023
Ad hoc: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
MANIFEST-2 [ … ]
Wed, 15.11.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, November 15, 2023
MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results
Phase 3 MANIFEST-2 topline results expected by the end of November, with detailed findings in oral presentation at ASH 2023
Monjuvi® U.S. net product sales of US$ 23.4 million (€ 21.5 million) for the third q [ … ]
Thu, 09.11.2023
MorphoSys AG
Conference Call Alert
Planegg/Munich, Germany, November 09, 2023
Invitation to MorphoSys’ Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023
MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the third quarter and first nine months 2023 on November 15, 2023, at 10:00 pm CET (09:00 [ … ]
Thu, 02.11.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, November 2, 2023
MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting
Following topline results expected in the coming weeks, the oral session at ASH 2023 in December will provide detailed findings from MANIFEST-2
Investor event foc [ … ]
Wed, 25.10.2023
MorphoSys AG
Planegg/Munich, Germany, October 25, 2023
MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023
Preliminary Q3 2023 Monjuvi U.S. net product sales of US$ 23.4 million (€ 21.5 million)
Preliminary Gross Margin for Monjuvi U.S. net product sales for Q3 2023 of 65%
Anticipate full y [ … ]